Prescriber Resources
Enrolling in REVLIMID REMS®
In order to prescribe REVLIMID, you must enroll in the REVLIMID REMS® program and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to the Celgene Customer Care at 1-888-432-9325.
Prescribing REVLIMID for your patients
In order to receive REVLIMID, your patients must also be enrolled in the REVLIMID REMS® program. You can enroll your patients and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.
Additionally, you can also enroll your patients by accessing the Celgene REMS mobile app for your iPad.
Learning more about REVLIMID REMS®
For additional information about the REVLIMID REMS® program, please see the educational materials below.
Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods:
REPORTING TO CELGENE |
|
Online: |
|
Email: |
|
Telephone: 1-908-673-9667 |
|
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or |
|
Fax: 1-908-673-9115 |
|
Mail to: Global Drug Safety & Risk Management |
|
Other: Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management |
REPORTING TO THE FDA |
|
Adverse drug experiences that are suspected to be associated with the use of REVLIMID and
|
|
Online: |
|
Telephone: 1-800-FDA-1088 |
|
Fax: 1-800-FDA-0178 |
|
Mail to: MedWatch |
For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2013-2019. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
